A 65-year-old woman achieved 15% weight loss on semaglutide over one year, improving her blood pressure, lipid profile, and sleep patterns. However, she experienced two falls and had pre-existing osteopenia, raising concerns about accelerated bone loss during rapid weight reduction. The clinical team revised their bone monitoring timeline from the standard 2-3 years to annual assessment based on emerging evidence. This case reflects a critical oversight in GLP-1 receptor agonist management that could affect millions of users. Rapid weight loss, particularly the 9-15% range commonly seen with semaglutide, may accelerate bone mineral density decline through reduced mechanical loading and hormonal changes. The growing popularity of these medications for weight management, combined with an aging population at higher fracture risk, creates an urgent need for updated clinical protocols. Standard osteoporosis monitoring intervals may be inadequate for patients experiencing substantial GLP-1-induced weight loss. The recommendation for enhanced protein intake and resistance training represents a proactive approach, but systematic studies examining optimal bone preservation strategies during GLP-1 therapy remain limited. This represents an important gap requiring immediate clinical attention.